Been pondering what we might be looking at revenue wise. Would love to know what smarter people than me think.
The original deal with Zeiss estimated a 5 year total of 20 Mil in revenue including 4 Mil in Milestone payments. That means something like 3 Mil year in sales. Let's say the addressable clinical market is about the same. I'm guessing we can get 1 to 1.5 Mil this Fin Year from sales to MRS. Enough to survive without another capital raising and then that 3 mil per year ongoing. Then there's another 3 Mil in annual sales to Zeiss when the product hits the market.
I'm thinking we should be looking at 10c a share with sales to MRS now and in a year or so 25c with sales to Zeiss kicking in.
Any alternate views?
Add to My Watchlist
What is My Watchlist?
